186 related articles for article (PubMed ID: 30935961)
1. SOX11 hypermethylation as a tumor biomarker in endometrial cancer.
Shan T; Uyar DS; Wang LS; Mutch DG; Huang TH; Rader JS; Sheng X; Huang YW
Biochimie; 2019 Jul; 162():8-14. PubMed ID: 30935961
[TBL] [Abstract][Full Text] [Related]
2. Hypermethylation of miR-203 in endometrial carcinomas.
Huang YW; Kuo CT; Chen JH; Goodfellow PJ; Huang TH; Rader JS; Uyar DS
Gynecol Oncol; 2014 May; 133(2):340-5. PubMed ID: 24530564
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer.
Huang YW; Liu JC; Deatherage DE; Luo J; Mutch DG; Goodfellow PJ; Miller DS; Huang TH
Cancer Res; 2009 Dec; 69(23):9038-46. PubMed ID: 19887623
[TBL] [Abstract][Full Text] [Related]
4. Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type.
Zighelboim I; Goodfellow PJ; Gao F; Gibb RK; Powell MA; Rader JS; Mutch DG
J Clin Oncol; 2007 May; 25(15):2042-8. PubMed ID: 17513808
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endometrial carcinomas.
Huang YW; Luo J; Weng YI; Mutch DG; Goodfellow PJ; Miller DS; Huang TH
Gynecol Oncol; 2010 May; 117(2):239-47. PubMed ID: 20211485
[TBL] [Abstract][Full Text] [Related]
6. Promoter hypermethylation of SOX11 promotes the progression of cervical cancer in vitro and in vivo.
Li X; Wu X; Li Y; Cui Y; Tian R; Singh N; Ding M; Yang Y; Gao Y
Oncol Rep; 2019 Apr; 41(4):2351-2360. PubMed ID: 30720133
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide DNA methylation sequencing reveals miR-663a is a novel epimutation candidate in CIMP-high endometrial cancer.
Yanokura M; Banno K; Adachi M; Aoki D; Abe K
Int J Oncol; 2017 Jun; 50(6):1934-1946. PubMed ID: 28440489
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation and histone modifications regulate SOX11 expression in lymphoid and solid cancer cells.
Nordström L; Andersson E; Kuci V; Gustavsson E; Holm K; Ringnér M; Guldberg P; Ek S
BMC Cancer; 2015 Apr; 15():273. PubMed ID: 25880212
[TBL] [Abstract][Full Text] [Related]
9. The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation.
Sernbo S; Gustavsson E; Brennan DJ; Gallagher WM; Rexhepaj E; Rydnert F; Jirström K; Borrebaeck CA; Ek S
BMC Cancer; 2011 Sep; 11():405. PubMed ID: 21943380
[TBL] [Abstract][Full Text] [Related]
10. The Dysregulation of SOX Family Correlates with DNA Methylation and Immune Microenvironment Characteristics to Predict Prognosis in Hepatocellular Carcinoma.
Qin S; Liu G; Jin H; Chen X; He J; Xiao J; Qin Y; Mao Y; Zhao L
Dis Markers; 2022; 2022():2676114. PubMed ID: 35465267
[TBL] [Abstract][Full Text] [Related]
11. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas.
Esteller M; Levine R; Baylin SB; Ellenson LH; Herman JG
Oncogene; 1998 Nov; 17(18):2413-7. PubMed ID: 9811473
[TBL] [Abstract][Full Text] [Related]
12. Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?
Kahn RM; Gordhandas S; Maddy BP; Baltich Nelson B; Askin G; Christos PJ; Caputo TA; Chapman-Davis E; Holcomb K; Frey MK
Cancer; 2019 Sep; 125(18):3172-3183. PubMed ID: 31150123
[TBL] [Abstract][Full Text] [Related]
13. Lynch syndrome-associated endometrial carcinoma with MLH1 germline mutation and MLH1 promoter hypermethylation: a case report and literature review.
Yokoyama T; Takehara K; Sugimoto N; Kaneko K; Fujimoto E; Okazawa-Sakai M; Okame S; Shiroyama Y; Yokoyama T; Teramoto N; Ohsumi S; Saito S; Imai K; Sugano K
BMC Cancer; 2018 May; 18(1):576. PubMed ID: 29783979
[TBL] [Abstract][Full Text] [Related]
14. RAB32 hypermethylation and microsatellite instability in gastric and endometrial adenocarcinomas.
Shibata D; Mori Y; Cai K; Zhang L; Yin J; Elahi A; Hamelin R; Wong YF; Lo WK; Chung TK; Sato F; Karpeh MS; Meltzer SJ
Int J Cancer; 2006 Aug; 119(4):801-6. PubMed ID: 16557577
[TBL] [Abstract][Full Text] [Related]
15. The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas.
Furlan D; Carnevali I; Marcomini B; Cerutti R; Dainese E; Capella C; Riva C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3329-36. PubMed ID: 16740754
[TBL] [Abstract][Full Text] [Related]
16. Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers.
Kanaya T; Kyo S; Maida Y; Yatabe N; Tanaka M; Nakamura M; Inoue M
Oncogene; 2003 Apr; 22(15):2352-60. PubMed ID: 12700670
[TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation of SOX11 correlates with adverse clinicopathological features of human prostate cancer.
Pugongchai A; Bychkov A; Sampatanukul P
Int J Exp Pathol; 2017 Dec; 98(6):341-346. PubMed ID: 29315911
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.
Cosgrove CM; Cohn DE; Hampel H; Frankel WL; Jones D; McElroy JP; Suarez AA; Zhao W; Chen W; Salani R; Copeland LJ; O'Malley DM; Fowler JM; Yilmaz A; Chassen AS; Pearlman R; Goodfellow PJ; Backes FJ
Gynecol Oncol; 2017 Sep; 146(3):588-595. PubMed ID: 28709704
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide DNA methylation profile of early-onset endometrial cancer: its correlation with genetic aberrations and comparison with late-onset endometrial cancer.
Makabe T; Arai E; Hirano T; Ito N; Fukamachi Y; Takahashi Y; Hirasawa A; Yamagami W; Susumu N; Aoki D; Kanai Y
Carcinogenesis; 2019 Jul; 40(5):611-623. PubMed ID: 30850842
[TBL] [Abstract][Full Text] [Related]
20. Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis.
Peterson LM; Kipp BR; Halling KC; Kerr SE; Smith DI; Distad TJ; Clayton AC; Medeiros F
Int J Gynecol Pathol; 2012 May; 31(3):195-205. PubMed ID: 22498935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
